A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder

scientific article published on July 2013

A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.4088/JCP.12M08093
P698PubMed publication ID23945458

P50authorAugustus John RushQ21104277
Maurizio FavaQ30089873
Roy H. PerlisQ88592183
Cristina CusinQ114238404
P2093author name stringAndrew A Nierenberg
Dan V Iosifescu
Nadia Iovieno
P433issue7
P921main subjectplacebo-controlled trialQ108853737
placeboQ269829
P304page(s)e636-41
P577publication date2013-07-01
P1433published inThe Journal of Clinical PsychiatryQ7743563
P1476titleA randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder
P478volume74

Reverse relations

cites work (P2860)
Q48073684Abnormal behaviours during pramipexole treatment for Cotard's syndrome: a case report.
Q40567300Analysis of pramipexole dose-response relationships in Parkinson's disease
Q38637621Backing into the future: pharmacological approaches to the management of resistant depression
Q37197216Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments
Q28265851Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans
Q57461556Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study
Q47123548Dopamine System Dysregulation in Major Depressive Disorders.
Q93184949Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study
Q47305318Imaging the role of inflammation in mood and anxiety-related disorders
Q38915253Inflammation Effects on Motivation and Motor Activity: Role of Dopamine
Q38574699Managing inadequate antidepressant response in depressive illness.
Q36091234Pharmacologic approaches to treatment resistant depression: Evidences and personal experience
Q26783002Pharmacological Approaches for Treatment-resistant Bipolar Disorder
Q26798241Pharmacological approaches to the challenge of treatment-resistant depression
Q37188026Pramipexole Impairs Stimulus-Response Learning in Healthy Young Adults
Q39301010Pramipexole augmentation in treatment-resistant major depressive disorder
Q39417632Psychiatric comorbidities in movement disorders.
Q35580361Rodent models of treatment-resistant depression.
Q35862776Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Q92384224Sleep therapeutics and neuropsychiatric illness
Q34550088Striatal dopamine D2/3 receptor availability in treatment resistant depression
Q95643359Structural Plasticity Induced by Ketamine in Human Dopaminergic Neurons as Mechanism Relevant for Treatment-Resistant Depression
Q38181363The integrative management of treatment-resistant depression: a comprehensive review and perspectives
Q38543238Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder

Search more.